Pierre Fargeot

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Fayette Jérôme; Penel Nicolas; Chevreau Christine; Blay Jean-Yves; Cupissol Didier; Thyss Antoine; Guillemet Cécile; Rios Maria; Rolland Frédéric; Fargeot Pierre; Bay Jacques Olivier; Mathoulin-Pelissier Simone; Coindre Jean Michel; Bui-Nguyen Binh
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Négrier Sylvie; Perol David; Ravaud Alain; Bay Jacques O; Oudard Stéphane; Chabaud Sylvie; Fargeot Pierre; Delva Remy; Deplanque Gael; Gravis Gwenaelle; Escudier Bernard;
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Culine Stéphane; Kramar Andrew; Théodore Christine; Geoffrois Lionel; Chevreau Christine; Biron Pierre; Nguyen Binh Bui; Héron Jean-François; Kerbrat Pierre; Caty Armelle; Delva Rémy; Fargeot Pierre; Fizazi Karim; Bouzy Jeannine; Droz Jean-Pierre;
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Pierre Fargeot (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Fayette Jérôme; Penel Nicolas; Chevreau Christine; Blay Jean-Yves; Cupissol Didier; Thyss Antoine; Guillemet Cécile; Rios Maria; Rolland Frédéric; Fargeot Pierre; Bay Jacques Olivier; Mathoulin-Pelissier Simone; Coindre Jean Michel; Bui-Nguyen Binh
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Investigational new drugs 2009;27(5):482-9.
2008: Négrier Sylvie; Perol David; Ravaud Alain; Bay Jacques O; Oudard Stéphane; Chabaud Sylvie; Fargeot Pierre; Delva Remy; Deplanque Gael; Gravis Gwenaelle; Escudier Bernard;
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5907-12.
2008: Culine Stéphane; Kramar Andrew; Théodore Christine; Geoffrois Lionel; Chevreau Christine; Biron Pierre; Nguyen Binh Bui; Héron Jean-François; Kerbrat Pierre; Caty Armelle; Delva Rémy; Fargeot Pierre; Fizazi Karim; Bouzy Jeannine; Droz Jean-Pierre;
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):421-7.
2007: Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier M-J; Audhuy B; Simon H; Montcuquet P; Eymard J-C; Walter S; Clavère P; Guastalla J-P;
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
British journal of cancer 2007;96(11):1633-8.
2006: Veyret Corinne; Levy Christelle; Chollet Philippe; Merrouche Yacine; Roche Henri; Kerbrat Pierre; Fumoleau Pierre; Fargeot Pierre; Clavere Pierre; Chevallier Bernard
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Cancer 2006;107(11):2535-44.
2006: Molucon-Chabrot Cécile; Isambert Nicolas; Benoit Laurent; Zanetta Sylvie; Fraisse Jean; Guilland Jean-Claude; Royer Bernard; Monin-Baroille Pascale; Flesch Michel; Fargeot Pierre; Coudert Bruno; Mayer Françoise; Fumoleau Pierre; Chauffert Bruno
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Anti-cancer drugs 2006;17(10):1211-7.
2006: Héry Michel; Bonneterre Jacques; Roché Henri; Luporsi Elisabeth; Kerbrat Pierre; Namer Moïse; Fumoleau Pierre; Monnier Alain; Fargeot Pierre
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.
Bulletin du cancer 2006;93(10):E109-14.
2006: Roché H; Kerbrat P; Bonneterre J; Fargeot P; Fumoleau P; Monnier A; Clavère P; Goudier M-J; Chollet P; Guastalla J-P; Serin D
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1221-7.
2006: Namer M; Fargeot P; Roché H; Campone M; Kerbrat P; Romestaing P; Monnier A; Luporsi E; Montcuquet P; Bonneterre J;
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):65-73.
2006: Fiedler W; Tchen N; Bloch J; Fargeot P; Sorio R; Vermorken J B; Collette L; Lacombe D; Twelves C;
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
European journal of cancer (Oxford, England : 1990) 2006;42(2):200-4.
2006: Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Luporsi E;
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):85-92.
2005: Campone M; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Fumoleau P
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1343-51.
2005: Praga Claudio; Bergh Jonas; Bliss Judith; Bonneterre Jacques; Cesana Bruno; Coombes R Charles; Fargeot Pierre; Folin Annika; Fumoleau Pierre; Giuliani Rosa; Kerbrat Pierre; Hery Michel; Nilsson Jonas; Onida Francesco; Piccart Martine; Shepherd Lois; Therasse Patrick; Wils Jacques; Rogers David
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4179-91.
2005: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Brémond Alain; Fumoleau Pierre; Namer Moïse; Goudier Marie-Josèphe; Schraub Simon; Fargeot Pierre; Chapelle-Marcillac Isabelle
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2686-93.
2004: Fargeot Pierre; Bonneterre Jacques; Roché Henri; Lortholary Alain; Campone Mario; Van Praagh Isabelle; Monnier Alain; Namer Moïse; Schraub Simon; Barats Jean-Claude; Guastalla Jean-Paul; Goudier Marie-Josèphe; Chapelle-Marcillac Isabelle
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4622-30.
2004: Thariat Juliette; Toubeau Michel; Ornetti Paul; Coudert Bruno; Berrielo-Riedinger Alina; Fargeot Pierre; Tavernier Christian; Brunotte François; Maillefert Jean Francis
Sensitivity and specificity of thallium-201 scintigraphy for the diagnosis of malignant vertebral fractures.
European journal of radiology 2004;51(3):274-8.
2004: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Fumoleau Pierre; Goudier Marie-Josèphe; Fargeot Pierre; Montcuquet Philippe; Clavère Pierre; Barats Jean-Claude; Monnier Alain; Veyret Corinne; Datchary Jean; Van Praagh Isabelle; Chapelle-Marcillac Isabelle
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3070-9.
2004: Bottomley Andrew; Biganzoli Laura; Cufer Tanja; Coleman Robert E; Coens Corneel; Efficace Fabio; Calvert Hilary Allan; Gamucci Teresa; Twelves Chris; Fargeot Pierre; Piccart Martine;
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2576-86.
2004: Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman R E; Calvert H A; Gamucci T; Twelves C; Fargeot P; Bottomley A;
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(7):1021-30.
2004: Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2004;53(3):233-8.
2003: Urien S; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Deporte-Fety R
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 2003;52(2):99-107.
2003: Fumoleau Pierre; Kerbrat Pierre; Romestaing Pascale; Fargeot Pierre; Brémond Alain; Namer Moïse; Schraub Simon; Goudier Marie-Jo; Mihura Jeanne; Monnier Alain; Clavère Pierre; Serin Daniel; Seffert Philippe; Pourny Christiane; Facchini Thomas; Jacquin Jean-Philippe; Sztermer Jean-François; Datchary Jean; Ramos René; Luporsi Elisabeth
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):298-305.
2002: Bonneterre J; Roché H; Monnier A; Guastalla J P; Namer M; Fargeot P; Assadourian S
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
British journal of cancer 2002;87(11):1210-5.
2002: Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert A H; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart M J
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3114-21.
2002: Riedinger J M; Eche N; Basuyau J P; Daver A; Touzery C; Mayer F; Coudert B; Fargeot P; Chauffert B; de Gislain C; Zanetta S
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]
Annales de biologie clinique 2002;60(2):183-91.
2001: Isambert N; Correia M; Cercueil J P; Zanetta S; Osmak L; Flesch M; Krause D; Coudert B; Fargeot P; Bedenne L; Chauffert B
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.
Journal of experimental & clinical cancer research : CR 2001;20(2):183-8.
2000: Laplanche A; Alzieu L; Delozier T; Berlie J; Veyret C; Fargeot P; Luboinski M; Lacour J
Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC).
Breast cancer research and treatment 2000;64(2):189-91.
2000: Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):50-5.
2000: Bastian G; Seitz J F; Moutardier V; Delperro J R; Fargeot P; Fraisse J; Formento P; Chazard M; Renée N; Milano G
Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):35-7.
2000: Roche H; Cure H; Adenis A; Fargeot P; Terret C; Lentz M A; Madelmont J C; Fumoleau P; Hanausk A; Chollet P
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.
Journal of neuro-oncology 2000;49(2):141-5.
2000: Arnal M; Franco N; Fargeot P; Riedinger J M; Brunet-Lecomte P; Lizard-Nacol S
Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer.
Breast cancer research and treatment 2000;61(1):13-20.
1999: Cure H; Souteyrand P; Ouabdesselam R; Roche H; Ravaud A; D'incan M; Viens P; Fargeot P; Lentz M A; Fumoleau P; Hanauske A; Chollet P
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Melanoma research 1999;9(6):607-10.
1999: Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset J L; Lentz M A; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3136-42.
1999: Lizard-Nacol S; Genne P; Coudert B; Riedinger J M; Arnal M; Sancy C; Brunet-Lecomte P; Fargeot P
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Anticancer research 1999;19(4C):3575-81.
1999: Lizard-Nacol S; Coudert B; Colosetti P; Riedinger J M; Fargeot P; Brunet-Lecomte P
Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.
Breast cancer research : BCR 1999;1(1):81-7.
1998: Degardin M; Oliveira J; Geoffrois L; Rolland F; Armand J P; Bastit P; Chauvergne J; Fargeot P; van Glabbeke M; Lentz M A; Tresca P; Boudillet J; Fumoleau P; Cappelaere P
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1103-7.
1997: Riedinger J M; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time]
Bulletin du cancer 1997;84(9):855-60.
1996: Coudert B; De Gislain C; Beltramo J L; Guigues B; Mayer F; Bruchon Y; Riedinger J M; Fargeot P; Dumas M; Guerrin J
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin]
Bulletin du cancer 1996;83(10):847-52.
1996: Riedinger J M; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV]
Bulletin du cancer 1996;83(8):654-63.
1996: Degardin M; Cappelaere P; Krakowski I; Fargeot P; Cupissol D; Brienza S
Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
European journal of cancer. Part B, Oral oncology 1996;32B(4):278-9.
1996: Misset J L; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1136-45.
1996: Urosevic V; Chollet P; Adenis A; Chauvergne J; Fargeot P; Roche H; Kerbrat P; Lentz M A; Fumoleau P; Chevallier B
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):181-2.
1995: Bui B N; Chevallier B; Chevreau C; Krakowski I; Peny A M; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2629-36.
1995: Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot J Y; Fargeot P; Olivier J P; Fizames C
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1564-71.
1995: Chauvergne J; Kerbrat P; Adenis A; Chollet P; Fargeot P; Pujade-Lauraine E; Dieras V; Madelmont J C; Lentz M A; Toulouse C
Phase II study of cystemustine in advanced renal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):130-1.
1994: Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]
La Clinica terapeutica 1994;145(8):113-21.
1993: Chauvergne J; Lhommé C; Rohart J; Héron J F; Ayme Y; Goupil A; Fargeot P; David M
[Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients]
Bulletin du cancer 1993;80(12):1069-79.
1993: Roché H; Guiochet N; Kerbrat P; Rebattu P; Fargeot P; Cattan A; Armand J P; Keiling R; Lentz M A; Van Glabeke M
Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
American journal of clinical oncology 1993;16(2):137-9.
1993: Douchez J; Droz J P; Desclaux B; Allain Y; Fargeot P; Caty A; Charrot P
Quality of life in long-term survivors of nonseminomatous germ cell testicular tumors.
The Journal of urology 1993;149(3):498-501.
1993: Chevallier B; Leyvraz S; Olivier J P; Fargeot P; Facchini T; Vo Van M L
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
Cancer investigation 1993;11(2):135-9.
1993: Chevreau C; Droz J P; Pico J L; Biron P; Kerbrat P; Cure H; Héron J F; Chevallier B; Fargeot P; Kramar A
Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial.
European urology 1993;23(1):213-7; discussion 218.
1993: Fumoleau P; Devaux Y; Vo Van M L; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Drugs 1993;45 Suppl 2():38-45.
1992: Garcia-Giralt E; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A; Guerin D; Guerin R
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Breast cancer research and treatment 1992;24(2):139-45.
1992: Avril M F; Bonneterre J; Cupissol D; Grob J J; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Fotemustine plus dacarbazine for malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1992;28A(11):1807-11.
1991: Bonneterre J; Kerbrat P; Fargeot P; Metz R; Roche H; Bastit P; Chevrier A; Tubiana-Hulin M; Geyer G; Cappelaere P
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(7):849-52.
1991: Boutan-Laroze A; Mahjoubi M; Droz J P; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin P M; Spielmann M; Rey A
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1690-4.
1990: de Gislain C; Dumas M; d'Athis P; Chapuis T; Mayer F; Fargeot P; Guerrin J; Escousse A
[Course of blood creatinine during repeated injections of cisplatin. Influence of drug combinations]
Thérapie 1990;45(5):423-7.
1990: Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):1063-9.
1990: Chauvergne J; Rohart J; Héron J F; Aymé Y; Berlié J; Fargeot P; George M; Lebrun-Jezekova D; Pigneux J; Chenal C
[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)]
Bulletin du cancer 1990;77(10):1007-24.
1990: Cappelaere P; Vignoud J; Fargeot P; Metz R; Chauvergne J; Meeus L; Schneider M; Chazard M
[Palliative chemotherapy of epidermoid carcinoma of the upper respiratory and digestive tracts with a combination of carboplatin and 5-fluorouracil]
Bulletin du cancer 1990;77(11):1099-105.
1990: Fargeot P
[Germ cell testicular tumors. Three therapeutic periods]
Bulletin du cancer 1990;77(4):331-9.
1989: Petrella T; Michiels J F; Michiels R; Collin F; Nabholtz J M; Friedman S; Fargeot P
CD 15 antigen in Hodgkin's disease.
Pathology, research and practice 1989;185(6):886-90.
1989: Lupera H; Droz J P; Piot G; Lapleige P; Fargeot P; Theodore C
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Oncology 1989;46(6):372-4.
1988: Bonneterre J; Mauriac L; Weber B; Roche H; Fargeot P; Tubiana-Hulin M; Sevin M; Chollet P; Cappelaere P
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
European journal of cancer & clinical oncology 1988;24(12):1851-3.
1988: Pfitzenmeyer P; Massin F; Fargeot P; Bonneau P; Michiels R; Jeannin L
[Pulmonary amyloidosis of the AA type associated with Hodgkin's disease]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1988;9(5):524-7.
1988: Chauvergne J; Cappelaere P; Clavel B; David M; Fargeot P; Meeus L; Traissac L; Klein T
[Randomized trial of initial chemotherapy with cisplatin alone or in combination in 241 advanced carcinomas of the upper respiratory and digestive tract]
Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris 1988;105(8):581-9.
1988: Chauvergne J; Cappelaere P; Fargeot P; Meeus L; Gary-Bobo J; Klein T; Clavel B; David M
[A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck. Analysis of a series of 209 patients]
Bulletin du cancer 1988;75(1):9-22.
1987: Droz J P; Fargeot P; Laplaige P; Moran-Ribon A; Piot G
Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
Progress in clinical and biological research 1987;243B():235-42.
1986: Hurteloup P; Armand J P; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
Phase II clinical evaluation of doxifluridine.
Cancer treatment reports 1986;70(6):731-7.
1986: Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand J P; Mathieu A; Tubiana M; Cappelaere P
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]
Acta clinica Belgica. Supplementum 1986;11():41-8.
1985: Bonneterre J; Coppens H; Mauriac L; Metz M; Rouesse J; Armand J P; Fargeot P; Mathieu M; Tubiana M; Cappelaere P
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
European journal of cancer & clinical oncology 1985;21(10):1153-8.
1984: De Jager R; Cappelaere P; Armand J P; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
European journal of cancer & clinical oncology 1984;20(11):1369-75.
1984: Fargeot P; Guerrin J
[Role of chemotherapy in adjuvant treatment of breast cancer: modulation of the immune status]
Bulletin du cancer 1984;71(4):346-53.
1980: Guerrin J; Fargeot P; de Gislain C; Mayer F; Rodriguez H; Massin F
[Adjuvant chemotherapy in treatment of non seminomatous germinal testicular tumor. Results and reflexions about 77 cases (author's transl)]
La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris 1980;56(5-6):209-13.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Pierre Fargeot

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Pierre Fargeot (preview)

All Publications